)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Arvinas (ARVN) investor relations material
Arvinas Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary4 Dec, 2025
Key pipeline updates
Advancing early-stage PROTAC pipeline with focus on LRRK2 degrader ARV-102 for Parkinson's and PSP, BCL6 degrader ARV-393 for B-cell malignancies, and KRAS G12D degrader ARV-806 for oncology indications.
Vepdegestrant, an estrogen receptor degrader, has a PDUFA date of June 5, 2026, for ESR1 mutant metastatic breast cancer.
ARV-027, a polyQ AR degrader, targets SBMA and is set for a phase I healthy volunteer study next year.
LRRK2 degrader (ARV-102) clinical progress
Phase 1 healthy volunteer study showed brain penetration, dose proportionality, and 75% LRRK2 degradation at 20-80 mg/day.
Biomarker reductions in neuroinflammation (GPNMB, IBA1, CD68) observed in healthy volunteers, outperforming competitor's inhibitor.
Multi-dose Parkinson's disease phase 1 cohorts enrolling, with results expected in early next year.
Phase 1b study in PSP planned for next year, followed by a potential registration-quality phase II study.
Development path for Parkinson's disease to be refined after competitor data readout in first half of next year.
Oncology pipeline highlights
ARV-393 (BCL6 degrader) in phase I for B-cell malignancies, with observed complete responses and plans for combination with Glofitamab.
Fast-to-market strategy includes monotherapy for AITL, an uncommon T-cell malignancy.
ARV-806 (KRAS G12D degrader) shows 25-40x preclinical potency over competitors and may overcome resistance due to KRAS overexpression.
Dose escalation for ARV-806 ongoing, with clinical data expected next year.
How will LUMA study results shape ARV-102 PD plan?
ARV-393: AITL fast-to-market vs. DLBCL combo?
What's the strategic shift behind ARV-027 SBMA?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arvinas earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arvinas Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer and other diseases. Utilizing its proprietary PROTAC® (Proteolysis Targeting Chimera) technology, Arvinas aims to degrade disease-causing proteins, which is a novel approach in the field of drug development. This technology harnesses the body's natural protein disposal system to selectively and efficiently remove aberrant proteins. The company's pipeline includes therapies targeting a range of diseases with significant unmet medical need, emphasizing oncology and neuroscience. The company is headquartered in New Haven, Connecticut, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage